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Cationic proteins found in cervicovaginal secretions (CVS) are known to contribute to the
early antiviral immune response against HIV-infection in vitro. We here aimed to define
additional antiviral factors that are over-expressed in CVS from female sex workers at high
risk of infection.
Methods
CVS were collected from Kenyan HIV-seronegative (n = 34) and HIV-seropositive (n = 12)
female sex workers, and were compared with those from HIV-seronegative low-risk women
(n = 12). The highly exposed seronegative (HESN) sex workers were further divided into
those with less (n = 22) or more (n = 12) than three years of documented sex work. Cationic
protein-depleted CVS were assessed for HIV-neutralizing activity by a PBMC-based HIV-
neutralizing assay, and then characterized by proteomics.
Results
HIV neutralizing activity was detected in all unprocessed CVS, however only CVS from the
female sex worker groups maintained its HIV neutralizing activity after cationic protein-
depletion. Differentially abundant proteins were identified in the cationic protein-depleted
secretions including 26, 42, and 11 in the HESN>3yr, HESN<3yr, and HIV-positive groups,
respectively. Gene ontology placed these proteins into functional categories including pro-
teolysis, oxidation-reduction, and epidermal development. The proteins identified in this
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study include proteins previously associated with the HESN phenotype in other cohorts as
well as novel proteins not yet associated with anti-HIV activities.
Conclusion
While cationic proteins appear to contribute to the majority of the intrinsic HIV neutralizing
activity in the CVS of low-risk women, a broader range of non-cationic proteins were associ-
ated with HIV neutralizing activity in HESN and HIV-positive female sex workers. These
results indicate that novel protein factors found in CVS of women with high-risk sexual prac-
tices may have inherent antiviral activity, or are involved in other aspects of anti-HIV host
defense, and warrant further exploration into their mode of action.
Introduction
HIV-seronegative women who have had frequent sexual HIV exposures over many years have been
shown to mount an efficient innate and HIV-specific immune response in the genital tract mucosa
despite their uninfected status [1]. HIV-neutralizing IgA and innate immune factors including
cationic proteins, CCR5-ligands and antiproteases have been found in genital tract secretions of
various HIV-exposed seronegative (HESN) cohorts such as female sex workers and HIV serodiscor-
dant couples [2–6]. Many cationic proteins have a synergistic antimicrobial effect and HIV neutral-
izing capacity in vitro [7], and constitute an important arm of innate immunity against pathogens
at genital mucosal surfaces. Expression of innate immune proteins is normally regulated by various
factors including sex hormones, inflammatory conditions and the local microflora [8–12]. Further-
more, their functional capacity can vary depending on their local distribution, concentration and
interaction with other molecules at the mucosal site [13]. The mechanisms of immune protection
from heterosexual transmission of HIV infection are thus complex and have not been extensively
studied in vivo. Mucosal samples collected fromHESN populations are a useful tool to complement
in vitro experiments and non-human primate studies to explore such local immune activities.
As genital secretions are known to contain many hundreds, if not thousands, of unique pro-
teins [14,15], many with antimicrobial and antiviral functions, it is likely that multiple factors
contribute to the host defense against HIV. This has however not been fully explored since
most studies have only examined predefined factors. Understanding the complexity of factors
contributing to HIV neutralizing activity can be performed comprehensively using systems
biology approaches. In the present study we examined cervicovaginal secretions (CVS) from
HIV-seronegative and HIV-seropositive female sex workers as well as CVS from HIV-seroneg-
ative low-risk women not participating in sex work. CVS samples were tested for HIV neutrali-
zation and were analyzed via mass spectrometry to identify proteins that could potentially be
contributing to this effect. Here, this study identified novel protein factors within the cationic
protein-depleted fraction of the mucosa that may be involved in the intrinsic antiviral nature
of cervicovaginal compartment and host defense against heterosexual HIV transmission in
addition to the well-described effects of various cationic proteins [7,16].
Material and Methods
Study population
HESN and HIV-seropositive female sex workers were recruited through the Pumwani Sex
Worker Cohort [17] and HIV-seronegative low-risk women were recruited through a Maternal
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Health Clinic based at the Pumwani Maternity Hospital [18]. All sex worker participants
enrolled were currently active in sex work whereas all low-risk women enrolled reported no
history of sex work. Although their partner was not tested for HIV serology these women were
considered to be significantly less exposed to HIV than the study participants in the sex worker
groups. All women underwent a full physical examination and sexually transmitted infections
(STI) testing at enrolment; diagnostics included HIV serology, urine for Chlamydia trachoma-
tis and Neisseria gonorrhoeaemolecular testing; syphilis serology; and Gram stain for Nugent
scoring. All participants were provided with HIV/STI prevention counseling, male and female
condoms, family planning services, treatment of STIs, medical care for acute and chronic ill-
nesses, access to adequate diagnostic testing and referral for specialist consultant and/or hospi-
talization as needed. This study was reviewed and approved by the research ethics boards at
Kenyatta National Hospital (Nairobi, Kenya); The Regional Ethical Review Board in Stock-
holm, Sweden; and the Research Ethics Board of the University of Manitoba (Winnipeg,
Canada). All study participants provided written informed consent.
Cervicovaginal Fluid Collection
CVS were collected by rotating a cotton swab 360° in the outer part of the endocervix and by
rotating a different swab across the vaginal wall. Both swabs were placed in the same tube con-
taining 0.5 ml sterile phosphate buffered saline, which was immediately placed on ice. The
samples were then transported from the clinic to the laboratory on ice and centrifuged at 800 g
for 10 minutes at 4°C. Supernatants were separated from the cell pellet and stored at -80°C.
HIV neutralization assay
HIV neutralization assays were performed according to a predefined protocol and neutralization
cut off [19,20]. Prior to this assay, the IgG fraction of the CVS samples from the HIV seropositive
women was removed to avoid IgG-mediated HIV-specific neutralizing activity [21]. The IgG-
depleted fraction was stored at -80°C until use. The other study groups were by definition HIV
IgG seronegative and their CVS samples were therefore left intact. For the HIV neutralizing
assay, an R5 tropic primary isolate of HIV subtype A (isolate 92UG037; AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH) was used. The CVS sample volume
did not allow assessment with additional virus isolates. To account for variations in TCID50
depending on PBMC donor variability, three viral dilutions were used in each assay and a
TCID50 of 10–50 was finally selected for evaluation. Duplicate wells of 75 μl of each virus dilution
and 75 μl of each sample fraction (undiluted) were incubated for 1 hour at 37°C followed by addi-
tion of a mixture of 1 x 105 PHA-P-stimulated PBMC from two donors. After 24 hour incubation
at 37°C, the cells were centrifuged; unbound virus was washed away, and 200 μl of fresh medium
were added to each well. On day 3, 120 μl of medium was discarded and replaced with new
medium, after which day 6 supernatants were collected for analysis of virus production with a
p24 antigen ELISA (Vironostika HIV-1 Antigen; Electra-Box Diagnostica AB, Stockholm, Swe-
den). Neutralization was defined as a67% reduction of p24 antigen in the supernatant as com-
pared with p24 antigen content when the virus isolate was incubated in the presence of a
standard pool of Swedish HIV seronegative heat-inactivated plasma samples diluted 1:20.
Selective depletion of cationic proteins from CVS
Carboxymethyl (CM) weak cation exchange resin (Bio-Rad) was used to deplete cationic pro-
teins from vaginal fluid [7]. The CM resin was pre-equilibrated by washing 6 times with a
buffer resembling vaginal fluid in electrolyte composition (60mMNaCl, 20mM potassium
phosphate, pH 6) [22]. Equal volumes of CVS from four to six HIV seronegative donors were
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centrifuged and pooled before the extraction of cationic proteins. From each pool, 0.5 mL CVS
was reserved and stored at -80°C as “unprocessed CVS”. The remaining volume from each
pool was CM-extracted by mixing with equilibrated CM resin at 4°C overnight in an end-over-
end tumbler. Centrifugation (15,000xg, 4°C, 3min) enabled collection of the CM-depleted CVS
supernatant, which was then cleared of residual resin by additional centrifugations and stored
at -80°C. The CM resin sediment was washed 5 times with 25mM ammonium acetate, pH 7,
and then cationic proteins were extracted by incubating the washed resin with 5% acetic acid in
a tumbler at 4°C. Extracted proteins were collected and stored at -80°C after 2 h, and the resin
was extracted a second time by incubation with more acetic acid overnight in a tumbler at 4°C.
The first and second cationic extracts were pooled, clarified of residual resin, concentrated by
vacuum centrifugation, and restored to the original volume. All samples were stored at -80°C
until use.
Protein Digestion and Preparation for MS Analysis
The protein content of the cationic protein-depleted CVS samples was measured by standard
BCA protein assay (Novagen). Ten micrograms from each sample was added to ammonium
bicarbonate buffer (100mM, Sigma) to a total volume of 100μl. Five microliters of dithiothreitol
(DTT, 200mM, Sigma) was added to each sample. Samples were vortexed, centrifuged and
incubated at 60°C while gently shaking for 1 hour. Twenty microliters of iodoacetamide
(200mM, Sigma) was then added to each sample. Samples were vortexed, centrifuged and incu-
bated at room temperature for 30 minutes in the dark. Eleven microliters of DTT (200mM)
was added after this 30 minute incubation to neutralize any further iodoacetamide activity (to
prevent alkylation of trypsin). Samples were again vortexed, spun down and incubated at room
temperature in the dark for 1 hour. Trypsin (Promega) was added (2ug/sample) and incubated
at 37°C overnight. Peptides were dried via vacuum centrifugation the following morning and
stored at -80°C. The samples were then cleaned of salts and detergents by reversed-phase liquid
chromatography (high pH RP, Agilent 1200 series micro-flow pump, Water XBridge column)
using a step-function gradient such that all peptides elute into a single fraction for each sample.
The fractions were then dried via vacuum centrifugation and kept at -80°C until analyzed by
mass spectrometry.
Mass Spectrometry Analysis
Fractions were re-suspended in 2% acetonitrile (Fisher Scientific), 0.1% formic acid (EMD
Canada) and injected into a nano-flow Easy nLC II connected in-line to an LTQ Orbitrap
Velos mass spectrometer with a nanoelectrospray ion source at 2.35 kV (Thermo Fisher Scien-
tific, San Jose, CA, USA). The peptide fractions were loaded onto a C18-reversed phase trap col-
umn (2 cm long, 100 μm inner diameter, 5 μm particles) with 100% buffer A (2% acetonitrile,
0.1% formic acid) at 3 μl/min for a total volume of 30 μl, and then separated on a C18-reversed
phase column (15 cm long, 75 μm inner diameter, 3 μm particles). Both columns were packed
in-house with ReproSil-Pur C18-AQ resin (Dr. Maisch) and fritted with Kasil. Peptides were
eluted using a linear gradient of 2–32% buffer B (98% acetonitrile, 0.1% formic acid) over 120
min at a constant flow rate of 250 nl/min. Total LC/MS/MS run-time was 160 minutes, includ-
ing the loading, linear gradient, column wash at 95% buffer B, and the equilibration.
Data were acquired using a data-dependent method, dynamically choosing the top 10 abun-
dant precursor ions from each survey scan for isolation in the LTQ (2.0m/z isolation width)
and fragmentation by CID (35% normalized collision energy, with 10 ms activation time). The
survey scans were acquired in the Orbitrap overm/z 300–1700 with a target resolution of
60000 atm/z 400, and the subsequent fragment ion scans were acquired in the LTQ Velos over
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a dynamicm/z range. The lower threshold for selecting a precursor ion for fragmentation was
1000 ions. Dynamic exclusion was enabled using a list size of 500 features, am/z tolerance of
15 ppm, a repeat count of 1, a repeat duration of 30 s, and an exclusion duration of 15 s, with
early expiration disabled. Lock Mass was used with polysiloxane. All spectra were processed
using Mascot Distiller v2.4.3.1 (Matrix Science) and database searching was done with Mascot
v2.4.0 (Matrix Science). Searches were against the SwissProt database (2013–04). The mini-
mum number of unique peptides required for protein identification was set to one peptide and
false discovery rates (Prophet) were required to be below 1% for both peptide and protein iden-
tification. Relative protein levels were calculated using label-free analysis based on precursor
ion peak intensities calculated using Progenesis LC-MS v.4.0 (Nonlinear Dynamics). Complete
details regarding the proteomic data set including normalized abundance, number of unique
peptides identified and percent coverage are available in S1 Table and are available online
(http://figshare.com/articles/Non_cationic_proteins_are_associated_with_HIV_neutralizing_
activity_in_genital_secretions_of_female_sex_workers/1428626).
Statistical & Bio-functional Analysis
Protein abundances were normalized by mean division and log2 transformation. Statistical
analysis was performed by Student’s T-tests (Perseus, v1.3.0.4, Max Planck Institute of Bio-
chemistry). The significance threshold was set as α = 0.05 and fold changes greater than or
equal to 2 (Log2 Fold Change = 1). Statistically significant results were entered into Ingenuity
Pathway Analysis (Qiagen), Database for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 [23,24] and examined using the UniProt website to determine bio-functional
associations. A minimum of two associated proteins and Benjamini-Hochberg corrected Fish-
er’s Exact Tests were used to determine significant bio-functional associations.
Results
Demographic data of the study groups
Analysis of CVS was performed by pooling samples from five to seven women into the follow-
ing study groups: HIV-seronegative low-risk women (low-risk, n = 12 into 2 pools), HESN
female sex workers (n = 34 into 6 pools, divided according to more (2 pools) or less (4 pools)
than 3 years of sex work), and HIV-seropositive female sex workers (HIV positive, n = 12 into
2 pools). Sample pooling was required due to the limited quantity of CVS collected and the
amounts required for the subsequent assays included in this study. The pools were designed to
contain comparable numbers of samples from women in the early and late menstrual cycle
stage, and comparable numbers of women using hormonal contraception (oral contraceptives,
n = 8, injectable contraceptives, n = 7 or no hormonal contraception use, n = 43) to limit poten-
tial confounding effects of the influence of sex hormones on the protein composition (data not
shown). None of the samples represented cases of ongoing infections with Chlamydia tracho-
matis, Neisseria gonorrhoeae or syphilis. Women with clinical signs of genital ulcers or inflam-
mation were excluded from the study. Bacterial vaginosis (here defined as gram stain for
Nugent scoring7) was diagnosed in 0 of 12 low-risk women, in 5 of 24 women in the
HESN<3yr sex worker group, in 1 of 12 women in the HESN>3yr sex worker group, and in 1
of 12 women in the HIV-seropositive sex worker group.
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Cationic protein-depleted CVS samples of the FSW study groups can
neutralize HIV
In the first set of experiments, the intrinsic HIV-neutralizing capacity was assessed in the
unprocessed sample pools. In a previous study the pools representing the low-risk study
group were shown to neutralize HIV as defined by a PBMC-based assay using a primary HIV
isolate of the R5 phenotype/subtype A [25]. Likewise, all pools representing the sex worker
(HESN>3yr, HESN<3yr and HIV positive) study groups were here shown to neutralize HIV
infection using the same experimental conditions (Fig 1). Next, the cationic proteins were
selectively removed from the CVS pools while sparing the concentrations of the remaining pro-
teins and other non-positively charged molecules. The removal of cationic proteins was con-
firmed by AU-PAGE for all pools (data not shown), thus suggesting that biologically relevant
concentrations were depleted. Traces of such peptide fragments could be detected by mass-
spectrometry; however the fragments detected may represent inactive remnants of the original
proteins (data not shown).
In our previous study we reported a lack of HIV-neutralizing activity in cationic protein-
depleted CVS of low-risk women [25]. Thus, the majority of the functional activity was medi-
ated by the cationic protein fraction for these low-risk uninfected women. To test whether this
effect was the same in high-risk groups, the sex worker study groups were assessed using the
same experimental conditions and showed significant HIV neutralizing activity despite the
Fig 1. HIV neutralizing activity in unprocessed and cationic protein-depleted cervicovaginal secretions. The HIV neutralizing activity of unprocessed
cervicovaginal secretions (CVS) and cationic protein-depleted CVS, respectively, was assessed in pooled samples from the study groups. Green bars: HIV
seronegative low-risk women (Low risk) [25]; Yellow bars: HIV seronegative women with less than 3 years of reported active sex work (HESN<3yr); Blue
bars: HIV seronegative women with more than 3 years of reported active sex work (HESN>3yr); Red bars: HIV seropositive sex working women (HIV
positive). The results shown are from two to three representative experiments using duplicate wells (median values ±SEM).
doi:10.1371/journal.pone.0130404.g001
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depletion of the cationic protein fractions (Fig 1). The sample pools representing the HIV posi-
tive women had been depleted of IgG prior to the cationic protein-depletion to exclude func-
tional activity mediated by HIV-specific IgG antibodies.
Proteomic analysis of cationic protein-depleted CVS from all study
groups
To define the proteins that were differentially expressed between the study groups, a
comprehensive analysis of the depleted fractions was performed by tandem-mass spectrometry
proteomic analysis. Relative protein levels were compared using a Student’s t-test (α = 0.05,
Fold Change2). Three comparisons were made: HESN>3yr versus low-risk women
(Table 1); HESN<3yr versus low-risk women (Table 2); and HIV positive sex workers versus
low-risk women (Table 3), which identified 26, 42, and 11 host differentially abundant pro-
teins, respectively.
The biological functions associated with the proteins identified as differentially abundant
were determined, and there were proteins associated with viral infection and HIV infection in
all sex worker groups. Both HESN groups (>3 years and<3 years) were found to differentially
express proteins known to have an effect on viral infection (CYCS, DNAJB1, MT2A, RPS27A,
CLTB, CTSB, HMGN2, ALB, ZYX) [27–34] with particular proteins known to increase HIV
infection according to the results of in vitromRNA silencing experiments (CYCS, DNAJB1,
MT2A, ZYX, PSME1, BANF1, RPS27A) [35,36]. Despite the depletion of cationic proteins and
the remaining expression of HIV infection enhancing proteins, the CVS of both HESN and
HIV-positive groups still maintained a relatively strong capacity to neutralize HIV. Other pro-
teins differentially expressed in these groups compared to the low-risk group included many
factors involved in the innate immune response, proteolysis, protease inhibition, oxidation
reduction, and others (Fig 2). Several of these proteins have known antimicrobial roles, such as
S100 proteins, mucins, leukocyte elastase inhibitor, and thioredoxin. Furthermore protein
S100A7, leukocyte elastase inhibitor, and thioredoxin were previously found to be overex-
pressed in HESN individuals in other proteomic studies [3,15].
Interestingly, three intracellular proteins were found to be commonly overabundant in the
cationic protein-depleted secretions of all HIV neutralizing groups: SH3 domain-binding glu-
tamic acid-rich-like protein 2 (SH3BGRL2), Synaptic vesicle membrane protein VAT-1 homo-
log (VAT-1) and Myristolyated alanine-rich C-kinase substrate protein (MARCKs). All three
were found at higher levels in the sex worker groups CVS than the CVS of low-risk women.
These proteins are associated with functions such as antioxidant defense, epidermal repair
and actin remodeling, respectively. Furthermore, there were two secreted proteins commonly
overabundant in the cationic protein-depleted secretions from both HESN groups: Poly(U)-
specific endoribonuclease (ENDOU) and Leukocyte elastase inhibitor (SERPIN B1), and two
secreted proteins commonly underabundant: Protein S100-A11 (S100A11) and Mucin-5AC
(MUC5AC). These factors are of particular interest due to their secreted nature and their
known antimicrobial and/or immune-related functions.
Discussion
This work demonstrates that genital secretions from HIV-seronegative and HIV-seropositive
sex workers have an intrinsic capacity to neutralize HIV in vitro, which extends previous find-
ings on low-risk uninfected women [7,25,37]. However in contrast, we here showed that when
cationic proteins were experimentally depleted from the samples of the female sex workers, the
HIV-neutralizing activity remained. Proteomic analysis revealed non-cationic proteins not
previously associated with antiviral activity to be present in the HIV-neutralizing secretions.
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This is the first time any HIV-neutralizing activity has been demonstrated in the cation-
depleted protein fraction of cervicovaginal mucosa.
Three proteins were found overabundant and common to all sex worker groups, including
SH3BGRL2, VAT-1 and MARCKS. None of these factors have been described to have direct
antiviral activity in the current literature, but we here speculate about their potential indirect
effects on various pathways involved in the mucosal defense against HIV infection. These pro-
teins are predominantly found intracellularly or within extracellular exosomes. VAT-1 is an
integral membrane protein that belongs to a superfamily of medium-chain dehydrogenases/
reductases and strongly resembles quinone oxidoreductases and zeta-crystallins [38]. VAT-1
has been shown to be an important calcium-regulated activator of epithelial cells which is
Table 1. Proteins found to be significantly overabundant (A) and under abundant (B) in the cationic protein-depleted cervicovaginal secretions of
HIV-exposed seronegative sex workers (>3 years) compared to HIV-seronegative low-risk controls.
Protein Name Gene
Name





Cytochrome c * CYSC Apoptosis/transport 6.351 0.043
DnaJ homolog subfamily B member 1 * DNAJB1 Stress response 5.340 0.001
Poly(U)-specific endoribonuclease ENDOU Immune response/proteolysis 4.757 0.049
60S ribosomal protein L4 RPL4 Translation 4.311 0.033
Eukaryotic translation initiation factor 2 subunit 2 EIF2S2 Protein biosynthesis 4.085 0.000
Caspase-14 CASP14 Epidermal differentiation 3.445 0.033
Microtubule-associated protein 4 MAP4 Cell division 2.731 0.004
Synaptic vesicle membrane protein VAT-1 homolog VAT1 Epidermal repair, oxidoreductase activity 2.674 0.027
Tubulin polymerization-promoting protein family
member 3
TPPP3 Microtubule bundle formation 2.606 0.017
Aldehyde dehydrogenase, dimeric NADP-preferring ALDH3A1 Catabolic process 2.415 0.026
SH3 domain-binding glutamic acid-rich-like protein
2
SH3BGRL2 Potential antioxidant defense 2.285 0.046
Nucleobindin-1 NUCB1 Calcium homeostasis 2.283 0.041
Myristoylated alanine-rich C-kinase substrate MARCKS Actin Cross-linking 2.191 0.047
Acyl-CoA-binding protein DBI Transport 2.146 0.018
Leukocyte elastase inhibitor SERPINB1 Protease Inhibition 1.871 0.015
UV excision repair protein RAD23 homolog B RAD23B Ubiquitin conjugation pathway 1.584 0.010
Vinculin VCL Cell adhesion 1.547 0.001
Lysosomal protective protein CTSA Proteolysis 1.453 0.032
Thioredoxin TXN Innate immune response, oxidoreductase
activity
1.330 0.034
Protein S100-A7 S100A7 Innate immune response 1.267 0.025
Barrier-to-autointegration factor * BANF1 Host-virus Interaction 1.143 0.032
(B) UNDERABUNDANT PROTEINS
Prothrombin F2 Acute phase response -4.092 0.014
Protein S100-A11 S100A11 keratinocyte differentiation -1.915 0.036
Mucin-5AC (Fragments) MUC5AC Mucosa component, anti-adhesion -1.734 0.035
Arachidonate 12-lipoxygenase, 12S-type ALOX12 Lipid metabolism -1.373 0.043
Keratin, type II cytoskeletal 6B KRT6B Structural -1.065 0.014
a General functions are based on each protein’s gene ontology obtained from the UniProt website.
b Statistical significance was deduced via Student’s T-test, p < 0.05.
* denotes a known association with HIV-1.
doi:10.1371/journal.pone.0130404.t001
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Table 2. Proteins found to be significantly overabundant (A) and under abundant (B) in the cationic protein-depleted cervicovaginal secretions of







Cytochrome c * CYCS Apoptosis/transport 6.344 0.001
DnaJ homolog subfamily B member 1* DNAJB1 Stress response 5.200 0.012
Hepatoma-derived growth factor HDGF Transcription regulation 4.874 0.041
Glutathione S-transferase P GSTP1 Anti-inflammation 4.446 0.008
Poly(U)-specific endoribonuclease ENDOU Immune response/proteolysis 4.097 0.044
60S ribosomal protein L4 RPL4 Translation 4.002 0.014
Quinone oxidoreductase PIG3 TP53I3 Stress response 3.665 0.025
BAG family molecular chaperone regulator 3 BAG3 Anti-apoptosis 3.584 0.009
Serum albumin ALB Acute phase response 3.542 0.012
Synaptic vesicle membrane protein VAT-1 homolog VAT1 Epidermal repair, oxidoreductase
activity
3.334 0.001
SH3 domain-binding glutamic acid-rich-like protein 2 SH3BGRL2 Potential antioxidant defense [26] 2.836 0.013
Heterogeneous nuclear ribonucleoprotein Q SYNCRIP Host-virus Interaction 2.542 0.006
Myristoylated alanine-rich C-kinase substrate MARCKS Actin cross-linking 2.317 0.000
Phosphoglucomutase-2 PGAM1 Glucose metabolism 2.286 0.027
Metallothionein-2 * MT2A Ion homeostasis 2.279 0.013
ADP-sugar pyrophosphatase NUDT5 Nucleotide metabolic process 2.205 0.025
Ubiquitin-40S ribosomal protein S27a * RPS27A Innate immune response 2.141 0.004
Nucleobindin-1 NUCB1 Calcium homeostasis 1.971 0.024
STE20-like serine/threonine-protein kinase SLK Apoptosis 1.909 0.047
Caspase-14 CASP14 Epidermal differentiation 1.908 0.029
Clathrin light chain B CLTB Vesicle-mediated transport 1.849 0.018
Proteasome activator complex subunit 1* PSME1 Immunoproteasome assembly 1.598 0.023
Lysosomal protective protein CTSA Proteolysis 1.564 0.028
Kallikrein-6 KLK6 Proteolysis 1.543 0.018
Barrier-to-autointegration factor * BANF1 Host-virus Interaction 1.538 0.015
Tubulin polymerization-promoting protein family member 3 TPPP3 Microtubule bundle formation 1.348 0.009
Leukocyte elastase inhibitor SERPINB1 Protease Inhibition 1.293 0.008
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial ECH1 Lipid metabolism 1.234 0.004
Cathepsin B CTSB Innate immune response/proteolysis 1.198 0.026
Ly6/PLAUR domain-containing protein 3 LYPD3 Cell-matrix adhesion 1.191 0.039
(B) UNDERABUNDANT PROTEINS
Non-histone chromosomal protein HMG-17 HMGN2 Chromatin organization -6.516 0.024
Coactosin-like protein COTL1 Defense response to fungus -5.413 0.017
Keratin, type II cytoskeletal 2 oral KRT76 Structural -4.856 0.027
Epidermal growth factor receptor kinase substrate 8-like
protein 1
EPS8L1 Cytoskeleton remodeling -3.318 0.038
Zyxin * ZYX Cell adhesion -2.753 0.025
BPI fold-containing family B member 1 BPIFB1 Innate immune response -2.388 0.049
Keratin, type II cytoskeletal 2 epidermal KRT2 Keratinization -2.188 0.041
Granulins GRN Inflammation, embryo implantation -2.087 0.011
IgGFc-binding protein FCGBP Maintenance of mucosal structure -2.052 0.044
Protein S100-A11 S100A11 keratinocyte differentiation -1.974 0.003
Mucin-5AC MUC5AC Mucosa component, anti-adhesion -1.708 0.015
(Continued)
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required for epidermal repair [39]. Elevated levels of epidermal repair proteins may be impor-
tant for maintaining an intact physical barrier within the genital tract which is critical for
preventing pathogen entry. VAT-1 also has the capacity to function as an oxidoreductase
which may further contribute to the overall antioxidant defense in the mucosa of the female
genital tract. SH3BGRL2 is believed to be another oxidoreductase belonging to the Thiore-
doxin-like superfamily as it has a homologous thioredoxin-like fold [26]. Certain Thioredoxin-
like family members such as peroxiredoxins have been shown to inhibit HIV replication in
vitro [40]. Based on SH3BGRL2’s homology with proteins known to affect pathways important
for HIV replication and known HIV inhibitors, it is an excellent biomarker for future studies.
MARCKS, on the other hand, has functions in cross-linking actin, binding calcium-calmodu-
lin, as well as integrins [41,42]. It has been speculated that these molecular functions contribute
to biological processes such as phagocytosis, secretion and/or membrane recycling which are
all important defense mechanisms against invading pathogens. As these proteins were all com-
monly overabundant in the secretions of sex workers compared to low-risk controls, they pres-








Phosphoglycerate mutase 1 PGM2 Glycolysis -1.028 0.028
a General functions are based on each protein’s gene ontology obtained from the UniProt website.
b Statistical significance was deduced via Student’s T-test, p < 0.05.
* denotes a known association with HIV-1.
doi:10.1371/journal.pone.0130404.t002
Table 3. Proteins found to be significantly overabundant (A) and under abundant (B) in the cationic protein-depleted cervicovaginal secretions of
HIV-positive sex workers compared to HIV seronegative low-risk controls.
Protein Name Gene
Name





Keratin, type I cytoskeletal 24 KRT24 Structural 5.049 0.015
SH3 domain-binding glutamic acid-rich-like protein
2
SH3BGRL2 Potential antioxidant defense [26] 2.826 0.018
Synaptic vesicle membrane protein VAT-1 homolog VAT1 Epidermal repair, oxidoreductase
activity
2.739 0.036
Myristoylated alanine-rich C-kinase substrate MARCKS Actin cross-linking 2.590 0.007
Phosphoglucomutase-2 PGM2 Glucose metabolism 1.735 0.037
60S acidic ribosomal protein P0 RPLP0 Host-virus interaction 1.717 0.039
UV excision repair protein RAD23 homolog B RAD23B Ubiquitin conjugation pathway 1.445 0.028
Vinculin VCL Cell adhesion 1.060 0.013
(B) UNDERABUNDANT PROTEINS
Keratin, type II cytoskeletal 2 oral KRT76 Structural -5.327 0.003
Transcobalamin-1 TCN1 Ion transport -2.994 0.038
Phosphoglycerate kinase 1 PGK1 Glycolysis -1.687 0.046
a General functions are based on each protein’s gene ontology obtained from the UniProt website.
b Statistical significance was deduced via Student’s T-test, p < 0.05.
doi:10.1371/journal.pone.0130404.t003
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Certain proteins that were found to be overabundant in the CVS of the HESN>3yr group
have previously been associated with protective immunity in comparable HIV-exposed sero-
negative cohorts including protein S100A7, leukocyte elastase inhibitor, and thioredoxin [3].
The family of S100 proteins, such as protein S100A7, includes calcium ion-binding proteins
that are known to be associated with native antimicrobial activity [43], are derived from epithe-
lial cells, and are secreted in response to external pathogens. Protein S100A7, also known as
Psoriasin has been specifically implicated in the innate immunity of the epidermis by enhanc-
ing barrier function via the promotion of keratinocyte differentiation and the strengthening of
tight junctions [44]. If and when protein S100A7 is induced under inflammatory conditions, it
is also known to play a role in the chemotaxis of immune cells including neutrophils and T
lymphocytes [45]. This protein’s association with increased barrier integrity could help prevent
infection and the recruitment of immune cells may help in viral clearance. However, the fine
interplay between the recruitment of HIV target cells for viral clearance versus infection propa-
gation is still not fully understood.
Thioredoxin (TXN) is a disulfide oxidoreductase with innate immune function as men-
tioned above. TXN plays key roles in reducing reactive-oxygen species-mediated inflammation
[46] and promoting cell growth and proliferation [47]. TXN also exhibits dose-dependent che-
motactic effects such that at low concentrations it is chemotactic for various immune cells
including neutrophils and at high concentrations it suppresses leukocyte chemotaxis and
extravasation [46,48]. Furthermore, there is evidence that TXN has the capacity to neutralize
HIV in macrophages in vitro, however it is noteworthy to mention that the same study found
that TXN’s cleavage product, Eosinophil cytotoxicity-enhancing factor had enhancing effects
on HIV infection and TXN is often quickly cleaved upon entering circulation [49]. It is there-
fore, hypothesized that it is more likely that secreted TXN exerts its protective effects by sup-
pressing leukocyte extravasation [46].
Leukocyte elastase inhibitor (SERPINB1), a protein associated with the HESN phenotype
in previous literature was also found commonly overabundant in both HESN groups in this
study [3]. SERPINB1 belongs to the serine protease inhibitor family of antiproteases, and
inhibits both elastase-like and chymotrypsin-like proteases, including Cathepsin G. It has been
implicated in providing defense against microorganisms at mucosal surfaces by protecting
against protease-mediated inflammatory damage of the epithelium induced during bacterial
infections, and promoting wound healing [50]. Other serine protease inhibitors such as Serpin
A1, Secreted leukocyte protease inhibitor and Elafin have been associated with anti-HIV func-
tionality in vitro [51–54]. Therefore, SERPINB1 may represent a novel target for further study
of its potential to neutralize HIV, thus preventing infection.
Poly(U)-specific endoribonuclease (ENDOU) was found commonly overabundant amongst
the CVS of HESN individuals within this study. ENDOU is a secreted endoribonuclease that
cleaves single-stranded RNA [55]. Based on the current literature, it is mostly commonly
expressed in placental tissue and in tumours. Not much is known about this protein making it
a novel protein for future studies.
Interestingly, there were also two proteins found commonly under abundant in the CVS of
HESN individuals compared to the CVS of low-risk women, protein S100A11 and Mucin
5-AC. S100A11 is also a member of the S100 family, a calcium ion-binding protein expressed
Fig 2. Biological processes of differentially abundant proteins between female sex worker and low-
risk groups. A: HIV-exposed seronegative female sex workers for a time greater than three yearsB: HIV-
exposed seronegative female sex workers for a time less than three years C:HIV-seropositive female sex
workers (DAVID Bioinformatics Resources 6.7, UniProt) (Blue bars represent overabundant proteins and red
bars represent under abundant proteins compared to the low-risk, uninfected control group).
doi:10.1371/journal.pone.0130404.g002
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by epithelial cells. S100A11 has a dual functionality in keratinocyte growth regulation such that
when it is found intracellularly, it suppresses growth and facilitates differentiation and cornifi-
cation of keratinocytes [56], whereas when it is found extracellularly, it in fact promotes kerati-
nocyte growth [57]. Mucin-5AC (MUC5AC) is a glycoprotein secreted on mucosal surfaces
generating another physical protective barrier against microorganisms. MUC5AC has been
shown to be induced from epithelial cells by neutrophil elastase in the airways, and may be
induced in a similar fashion at other mucosal sites such as the female genital tract [58].
The up-regulation and down-regulation of specific factors at the mucosa of the female geni-
tal tract of HIV-exposed sex workers such as those identified in this study may be a result of
frequent sexual encounters, their higher risk of genital exposure to seminal fluid from different
individuals, and/or from previous STIs. These are all known risk factors for inflammation, dis-
rupted genital microflora and altered composition of the innate immune proteome [59]. It is
possible that the up-regulation of some of these factors may be the result of increased Toll-like
receptor (TLR) expression in the cervical epithelial cells of HIV-resistant women [60]. Further
fractionation is needed to define which of these factors constitute the majority of the non-cat-
ionic protein neutralizing activity. Furthermore, only Clade A isolates were tested in this study,
therefore we can only attest to the enhanced neutralizing activity of the cationic protein-
depleted secretions of female sex workers against these isolates. It is also possible that HIV neu-
tralizing IgA antibodies [19,61] as well as other peptides, below the detection limit of the mass
spectrometry analysis, were present and associated with HIV-neutralizing activity. In any case
the factors identified in this study and their HIV inhibitory capacity warrant further investiga-
tion in vitro.
Understanding factors that modulate HIV infection at the female genital tract mucosa is
important for the development and implementation of novel antiviral compounds including
microbicides. This study increases our knowledge of the neutralizing capacity of genital secre-
tions and identifies new potential antimicrobial factors important for female genital tract
immunity.
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